Antibiotic Pioneers Increasingly Looking to Emerging Markets For Partners
China Becoming A ‘Hub’ For Antibacterial Development And Commercialization
Small- to medium-sized drug makers developing new products for resistant infections are increasingly partnering with players in emerging markets such as China because of the absence of workable risk/reward systems in rich countries, according to a report by The Access To Medicine Foundation.
You may also be interested in...
Akebia brings in Cyclerion’s diabetes candidate praliciguat, plus deals involving Genmab/Bolt, Auris/Trasir, Zymergen/Lodo, Bavarian Nordic/Dynavax and more.
Only two new antibiotics are in Phase III trials for gonorrhea: Entasis’ zoliflodacin, in collaboration with the Global Antibiotic R&D Partnership, and GlaxoSmithKline’s gepotidacin in partnership with the US Biomedical Advanced R&D Authority.
Novo Holdings’ REPAIR Impact Fund has opened a global ‘AMR talent contest’ to groups developing new antimicrobial treatments, offering direct investment as the prize.